BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cytochroma Inc. Announces New Appointments to Its Boards of Directors


6/13/2011 8:20:02 AM

MARKHAM, ON, June 13, 2011 /PRNewswire/ - Cytochroma today announced the appointment of Dr. Cynthia Lavoie and Mr. Osamu Otani to its Board of Directors. Dr. Lavoie replaced Dr. Luc Marengère as VG Partners' representative, and Mr. Otani replaced Dr. Seiichi Kiso as Mitsubishi Tanabe Pharma Corporation's representative on the Company's Board. The number of Board members remains unchanged at six members.

"We are pleased to have Cynthia and Osamu join the Cytochroma Board. They bring complementary skills in finance and drug development, which will provide immediate benefits to the Company and position Cytochroma for great success," stated Dr. Alan Lewis, Chairman of Cytochroma's Board of Directors. "We are deeply indebted to Luc and Seiichi for their strong contributions to the Cytochroma Board of Directors and we wish them well."

Dr. Lavoie is a Partner with VG Partners, part of VenGrowth Private Equity Partners Inc., and co-heads the management of the VenGrowth Advanced Life Sciences Fund Inc. She brings over 16 years of experience in research and industry and works closely with Company management lending her technical and financial expertise to operations as well as financing, merger and exit transactions. Dr. Lavoie is currently on the boards of Axela, Interface Biologics, Trillium Therapeutics and Zelos Therapeutics. Her prior experience includes positions as Investment Manager with the Ontario Genomics Institute where she initiated a seed financing program and as Marketing Strategy Consultant with a medical device and therapeutics company.

Mr. Otani joined Tanabe Seiyaku Company Ltd. in 1983, and has served in managerial positions across International Development and Project Management, including General Manager, Tanabe Seiyaku London Office, and Managing Director, Mitsubishi Pharma Research & Development (Beijing). He has been President, Mitsubishi Tanabe Pharma Development America, Inc. since July 2010.

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease (CKD). The Company specializes in developing new therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma also has a portfolio CYP24 and phosphate-uptake inhibitors in early stage development.

For more information about Cytochroma, please visit www.cytochroma.com.

SOURCE Cytochroma



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES